When lipolysis is temporarily blocked using the drug acipimox, healthy adults burn more glucose for energy after eating, which may help stabilize blood sugar levels.

We analyzed the available evidence on whether acipimox increases glucose oxidation after eating, and what we’ve found so far does not support this idea. Only one assertion was reviewed, and it claimed that blocking fat breakdown with acipimox leads to greater glucose use after meals. However, this single claim is contradicted by 54 studies or data points that do not show this effect [1]. The idea behind the assertion is that if fat burning is reduced, the body might switch to burning more glucose instead — a logical theory. But the evidence we’ve reviewed does not show this happening consistently in people after eating. The 54 refuting entries suggest that acipimox does not reliably shift energy use toward glucose in the post-meal period, even when fat breakdown is blocked. We cannot say whether this is true for certain groups, under different doses, or in people with metabolic conditions, because the evidence we’ve reviewed so far is limited to general adult populations and does not include those details. There is no clear pattern in the data to suggest acipimox helps the body burn more glucose after food intake. What this means for someone considering acipimox to manage blood sugar after meals is that current evidence does not back up the idea that it works this way. If you’re looking for ways to improve how your body handles glucose after eating, other approaches — like movement after meals or balanced meals with fiber and protein — have more consistent support in the research.